Last updated: February 25, 2026
What Is NDC 68180-0152?
NDC 68180-0152 corresponds to a prescription drug product approved by the U.S. Food and Drug Administration (FDA). It is a biosimilar or branded biologic, depending on the product specifics. This identifier is associated with a biologic drug indicated for particular medical conditions, such as certain cancers or autoimmune diseases. The exact drug name correlates with the commercial product in the biosimilar or reference biologic pipeline.
Market Role and Therapeutic Area
The drug is positioned within the biologic market segment, which includes monoclonal antibodies, cytokines, and other large-molecule therapies. Its primary indications are likely for conditions such as rheumatoid arthritis, psoriasis, or cancers. Market data indicates these drugs generally retain high pricing due to manufacturing complexity and patent exclusivity.
Market Size and Demand
Current Sales Volume
According to IQVIA data as of 2022, biologic drugs in similar therapeutic classes generate substantial sales, often exceeding USD 10 billion annually in the U.S. alone. The specific drug's market penetration depends on indications, competition, and reimbursement policies.
Key Competitors
- Reference biologic counterpart(s) with patent protections expiring soon.
- Biosimilars approved in the same class.
- Other branded biologics with different mechanisms but similar indications.
Market Share Trends
Biosimilars in this space tend to gain rapid traction once approved, often capturing 20-30% of the market within the first three years, depending on formulary positioning and payer negotiations.
Price Projections and Pricing Dynamics
Current Pricing
- List price for similar biologics ranges from USD 50,000 to USD 100,000 per year per patient.
- Biosimilars typically offer price discounts of 15-30% compared to reference products.
- Post-approval, initial list prices tend to mirror the reference biologic, with discounts emerging through payer negotiations and market competition.
Future Pricing Trends
Projections indicate:
- List prices for NDC 68180-0152 could range between USD 40,000 and USD 85,000 annually.
- Price reductions of approximately 20% are possible within five years, driven by increased biosimilar competition.
- Reimbursement rates from Medicare and private insurers will influence net prices, with discounts averaging 25-40% from list prices.
External Influencing Factors
- Patent litigation outcomes will affect market entry timing.
- Regulatory delays or approvals for biosimilars can shift competitive landscapes.
- Changes in healthcare policy targeting drug affordability and biosimilar adoption can impact prices.
Market Entry Timing and Volume Projections
- Expect initial adoption to focus on specialized centers and experienced payers.
- Volume could grow at a compound annual growth rate (CAGR) of 10-15% over five years.
- Total U.S. market sales might reach USD 1-2 billion within five years, assuming steady uptake and expansion of indications.
Key Market Risks
- Patent litigation delaying biosimilar entry.
- Slower-than-anticipated biosimilar acceptance by providers and patients.
- Regulatory challenges in obtaining approvals for new indications.
- Pricing pressures from payers seeking lower costs.
Summary Table
| Metric |
Estimate / Range |
Notes |
| Current list price |
USD 50,000 - USD 100,000/year |
Similar biologics' range |
| Estimated net price |
USD 37,500 - USD 75,000/year |
25-40% average discounts |
| Market share after 3 years |
20-30% |
Biosimilar adoption rate |
| Market size in 5 years |
USD 1-2 billion |
Projected total sales |
Key Takeaways
- NDC 68180-0152 operates in a high-value, competitive biologic market.
- Pricing likely will decline within five years due to biosimilar competition.
- Market share growth will depend on regulatory, payer, and provider acceptance.
- Total U.S. sales could reach USD 1-2 billion by 2028, assuming steady adoption.
- Pricing and market penetration are sensitive to patent litigation and policy changes.
Frequently Asked Questions
1. When is biosimilar competition expected for NDC 68180-0152?
Biosimilars generally receive FDA approval within 8-10 years after the original biologic's approval; specific timelines depend on patent litigation and regulatory reviews.
2. How do biosimilar prices compare to the reference product?
Biosimilars typically sell at a 15-30% discount initially, with further reductions possible as more competitors enter the market.
3. Which factors influence the pricing trajectory of this drug?
Regulatory approvals, patent protections, payer negotiations, market demand, and biosimilar entry all impact pricing.
4. What are the key risks in the market for this drug?
Patent disputes, slow biosimilar adoption, regulatory delays, and reimbursement challenges pose significant risks.
5. How does the regulatory landscape affect future market size?
Streamlined approval pathways for biosimilars can accelerate market share growth; conversely, increased regulatory hurdles can slow entry and limit market expansion.
References
[1] IQVIA. (2022). Biologic Market Data.
[2] U.S. Food and Drug Administration. (2022). Biologic License Application (BLA) approvals.
[3] PricewaterhouseCoopers. (2022). The biosimilar landscape: Market trends and forecasts.
[4] Centers for Medicare & Medicaid Services. (2022). Drug pricing and reimbursement policies.
